- Trials with a EudraCT protocol (64)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
64 result(s) found for: Cognitive Impairment AND Memory Disorders.
Displaying page 1 of 4.
EudraCT Number: 2014-003117-28 | Sponsor Protocol Number: EPU-P77 | Start Date*: 2014-11-03 | ||||||||||||||||
Sponsor Name: | ||||||||||||||||||
Full Title: Can Methylphenidate (Ritalin) improve memory and attention in mild cognitive impairment? An EEG study | ||||||||||||||||||
Medical condition: memory impairment in patients with Mild Cognitive Impairment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001975-12 | Sponsor Protocol Number: V00191 PO 202 | Start Date*: 2007-07-18 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT - IDPF | |||||||||||||
Full Title: Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel... | |||||||||||||
Medical condition: Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) FI (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006195-39 | Sponsor Protocol Number: EarlyAD-PET | Start Date*: 2012-02-29 | |||||||||||||||||||||
Sponsor Name:Skånes universitetssjukhus | |||||||||||||||||||||||
Full Title: An open-label study to compare the prognostic value of (18F)Flutemetamol PET-imaging with longitudinal biomarker data in healthy volunteers and patients with mild cognitive impairment | |||||||||||||||||||||||
Medical condition: Dementia and cognitive impairment; in particular mild cognitive impairment and Alzheimer's disease | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002226-11 | Sponsor Protocol Number: SIMaMCI | Start Date*: 2008-10-07 |
Sponsor Name:Charité - Unversitätsmedizin Berlin | ||
Full Title: Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients | ||
Medical condition: Amnestic mild cognitive impairment (MCI) denotes clinical conditions in the border zone between normal cognitive functioning and dementia. The definition of amnestic MCI by Petersen and his co-work... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003111-58 | Sponsor Protocol Number: AD-4833/TOMM40_301 | Start Date*: 2013-09-20 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd | |||||||||||||
Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s... | |||||||||||||
Medical condition: Mild cognitive impairment due to Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000762-29 | Sponsor Protocol Number: COLAL/11/2016 | Start Date*: 2017-10-09 | ||||||||||||||||
Sponsor Name:MDM S.P.A. | ||||||||||||||||||
Full Title: CHOLINA ALPHOSCERATE INJECTION VERSUS CITICOLINE INJECTION IN ELDERLY PATIENTS WITH COGNITIVE IMPAIRMENT RESULTING FROM CEREBROVASCULAR EVENT | ||||||||||||||||||
Medical condition: Cognitive impairment resulting from cerebrovascular event. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001599-12 | Sponsor Protocol Number: 18F-AV-45-C01 | Start Date*: 2014-03-04 |
Sponsor Name:VU University Medical Center (VUmc) | ||
Full Title: The clinical value of amyloid imaging with [18F]-AV45 in a population of memory clinic patients | ||
Medical condition: The total number of inclusion in this study is 170 subjects; 140 patients (including Alzheimer’s disease (AD) patients, patients with mild cognitive impairment (MCI), patients with subjective memor... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014810-87 | Sponsor Protocol Number: CL2-NEURO-005 | Start Date*: 2010-07-22 |
Sponsor Name:INSTITUT DE RECHERCHES INTERNATIONALES SERVIER | ||
Full Title: Effect of Memantine 20 mg (Ebixa) and Donepezil 5 mg (Aricept) on motor cortex plasticity induced by paired associative stimulation using transcranial magnetic stimulation (TMS) in patients sufferi... | ||
Medical condition: - Patients suffering from Mild Cognitive Impairment (memory problems, objective memory disorder, absence of other cognitive disorders or repercussions on daily life, normal general cognitive functi... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-010227-62 | Sponsor Protocol Number: GE-067-005 | Start Date*: 2009-09-09 | |||||||||||
Sponsor Name:GE Healthcare Ltd and its Affiliates | |||||||||||||
Full Title: A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (F18) Injection for Identifying Subjects with Amnestic Mild Cognitive Impairment who will Convert to Probable Alzhei... | |||||||||||||
Medical condition: GE-067-005 will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer for predicting the conversion from amnestic Mild Cognitive Impairment to probable Alzheimer’s disease. Uptake... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003473-94 | Sponsor Protocol Number: UCL-2016-121 | Start Date*: 2019-05-20 |
Sponsor Name:Cliniques Universitaires Saint-Luc | ||
Full Title: Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms. | ||
Medical condition: Alzheimer’s disease (AD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000778-46 | Sponsor Protocol Number: LiBiDi-EK314/11 | Start Date*: 2013-01-17 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Forschungszentrum Jülich GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Elucidation of Lithium Working Mechanism in Bipolar Disorder by means of Multi Modal Brain Imaging (LiBiDi) | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers Bipolar patients type 1 | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005024-37 | Sponsor Protocol Number: 202100647 | Start Date*: 2022-01-24 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease | ||
Medical condition: - Alzheimer's disease - Mild Cognitive Impairment - Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000618-32 | Sponsor Protocol Number: GNC-501 | Start Date*: 2022-09-29 | ||||||||||||||||
Sponsor Name:GENEURO SA | ||||||||||||||||||
Full Title: Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID-19 or Postacute Sequelae of COVID-19 (PASC) Sy... | ||||||||||||||||||
Medical condition: Postacute Sequelae of COVID-19 (PASC) Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004498-18 | Sponsor Protocol Number: HUB-NEU-2019-01 | Start Date*: 2020-06-30 | |||||||||||
Sponsor Name:Dr. Jordi Gascón / Dra. Lola Ledesma | |||||||||||||
Full Title: EFFICACY AND SAFETY CLINICAL TRIAL WITH EFAVIRENZ IN PATIENTS DIAGNOSED WITH ADULT NIEMANN-PICK TYPE C WITH COGNITIVE IMPAIRMENT | |||||||||||||
Medical condition: Niemann Pick tipo C (NPC) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003825-27 | Sponsor Protocol Number: 263CS201 | Start Date*: 2020-06-02 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002171-11 | Sponsor Protocol Number: 010622 | Start Date*: 2024-07-02 |
Sponsor Name:Medical University of Łódź | ||
Full Title: Randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of dimethyl fumarate in brain atrophy reduction, synaptic functional connectivity, cognitive functions, quality of ... | ||
Medical condition: dementia and mild cognitice impairment due to Alzheimer's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005633-33 | Sponsor Protocol Number: 202000842 | Start Date*: 2021-06-02 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine | ||
Medical condition: A depressive disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003796-17 | Sponsor Protocol Number: CST103/CST139-CLIN-010 | Start Date*: 2020-10-22 | ||||||||||||||||
Sponsor Name:CuraSen Therapeutics, Inc. | ||||||||||||||||||
Full Title: An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cognition After Oral Administration of CST-103 or CST-139 | ||||||||||||||||||
Medical condition: Patients with Mild Cognitive Impairment or Parkinson’s Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002147-34 | Sponsor Protocol Number: AZT-001 | Start Date*: 2016-01-21 | |||||||||||
Sponsor Name:AZTherapies, Inc. | |||||||||||||
Full Title: A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease. | |||||||||||||
Medical condition: Early stage of Alzheimer's Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003834-34 | Sponsor Protocol Number: NBI-1065844-CIAS2023 | Start Date*: 2023-02-23 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizop... | |||||||||||||
Medical condition: Cognitive Impairment Associated With Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
